Tibet Haisco Pharmaceutical Co. Ltd. has divulged myosin-2 (MYH2) inhibitors reported to be useful for the treatment of muscular dystrophy.

Haisco Pharmaceutical Group Co. Ltd. has discovered sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.

Blueprint Medicines Corp. has synthesized Cyclin-dependent kinase 2 (CDK2) inhibitors reported to be useful for the treatment of cancer.

Jiangsu Mingsheng Jutai Biotechnology Co. Ltd. has patented β-catenin (CTNNB1)/BCL9 interaction inhibitors reported to be useful for the treatment of cancer and fibrosis.

Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has discovered estrogen-related receptor α (ERRα; ERR1) inverse agonists reported to be useful for the treatment of cancer, obesity, hypertension, gallstone, osteoporosis, metabolic syndrome, hyperuricemia and Alzheimer's disease.

Blueprint Medicines Corp. has identified cyclin-dependent kinase 2 (CDK2) inhibitors reported to be useful for the treatment of cancer.

A Suzhou Puhe Biopharma Co. Ltd. patent reports new Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors described as potentially useful for the treatment of cancer.

Cyclin-dependent kinase 12 (CDK12)/cyclin K and CDK13/cyclin K inhibitors have been described in a Nanjing Sanhome Pharmaceutical Co. Ltd. patent and are reported to be potentially useful for the treatment of cancer.

Insilico Medicine Inc. has prepared and tested new spirocyclic mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer and viral infections.

Camptothecin derivatives reported to be useful for the treatment of cancer have been disclosed in a recent Genescience Pharmaceuticals Co. Ltd. patent.